Consumers express concerns over respiratory complications
Smoking has long been established as a risk factor for respiratory disease and health officials are now reporting that smokers with COVID-19 are more likely to face serious complications. Recent studies have found that smokers with COVID-19 are 14 times more likely to need intensive care than non-smokers.
Now a new article from ResearchandMarkets.com underscores that point. The title says it all: “Smoking Cessation Sees 122% Growth as Public Seek to Reduce Risk of COVID-19”
This has caused a surge in demand for smoking cessation products such as nicotine replacements and behavioral supports as people try to protect themselves and strengthen their lungs. Sales of nicotine replacement products increased by 54% in the third week of March and helplines have reported an increase in callers concerned about the coronavirus. Companies like Pivot and Quit Genius have responded to the growing interest by offering free trials of their coaching and support apps while Lucy, a seller of nicotine gum and lozenges, has seen sales rise by 75% in the past month.
Included is recent research within the U.S. Smoking Cessation market; research that allows professionals to:
- Track competitor drugs sales and market share in the US Smoking Cessation market
- Track competitive developments in Smoking Cessation market and present key issues and learnings
- Synthesize insights for Smoking Cessation market and products to drive business performance
- Answer key business questions about the Smoking Cessation market
- Evaluate commercial market opportunity assessment, positioning, and segmentation for Smoking Cessation products
- Supports decision making in R&D to long term marketing strategies
- Support monitoring and reporting national Smoking Cessation market analysis and sales trends
